Table 12 Selected phase I-II clinical trials conducted with Obatoclax as a single (−single-) or combined therapeutic in untreated/pre-treated or non-refractory(−)/refractory (Refrac) patients with Carboplatin (CARB), Etoposide (ETOP) or Topotecan (TOPOT) against extensive-stage small cell lung cancer (es-SCLC), Myelodysplastic Syndrome (MDS), Hodgkin’s Lymphoma (HL), Myelofibrosis (MFS), advanced Chronic Lymphocytic Leukemia (a-CLL), and Hematologic Malignancies (HM). Adverse effects are abbreviated as Neut (Neutropenia), Anem (Anemia), Euph (Euphoria), Dizz (Dizziness), Naus (Nausea), Atax (Ataxia) and Throm (Thrombocytopenia). Disease stabilization effects on patient numbers (expressed as a percentage (%) of the whole group or as positive responders/group size) are highlighted in weeks (>wks). Unavailable data for disease stabilization effects is highlighted by ‘-‘. The clinical trials reference numbers highlighted in bold (left column) and their corresponding references highlighted in the columns on the right (Ref)
Obatoclax | Phase | Patients | Refrac | Combined | Disease | Adverse Effects | Stabilization | Ref |
|---|---|---|---|---|---|---|---|---|
NCT00684918 | I/II | Untreated | – | -single- | AML | Neut | 4/19 for 11 cycles | [408] |
NCT00682981 | II | Untreated | – | CARB/ETOP | es-SCLC | Neut/Anem | – | [409] |
NCT00413114 | II | Untreated | – | -single- | MDS | Euph/Naus | 50% (> 12 wks) | [410] |
NCT00359892 | II | – | Yes | -single- | HL | Euph/Dizz | 38% (> 8 wks) | [411] |
NCT00521144 | II | Pre-treated | Yes | TOPOT | SCLC | Throm/Neut/Anem/Atax | 56% (Phase II) | [412] |
NCT00360035 | II | Pre-treated | – | -single- | MFS | Atax/Anem/Throm | – | [413] |
NCT00600964 | I/II | Pre-treated | Yes (22/26) | -single- | a-CLL | Atax/Euph/Anem/ Throm | – | [414] |
NCT00438178 | I | N/A | Yes | -single- | HM | Neut/Anem/Throm | – | [415] |